LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment

Autor:	Rajender Singh Arora, Chiun-Sheng Huang, Sara A. Hurvitz, Binghe Xu, Jozef Sufliarsky, Annick Lahogue, Martine Piccart-Gebhart, Young-Hyuck Im, Nadia Harbeck, Linu Abraham Jacob, Keun-Seok Lee, Elzbieta Staroslawka, Marek Z. Wojtukiewicz, Martina Uttenreuther-Fischer, Shukui Qin, Seock-Ah Im, Ajay O. Mehta, Qiang Sun, Jacek Jassem, Jin-Hee Ahn
Rok vydání:	2012
Předmět:	Oncology Cancer Research medicine.medical_specialty ERBB Family business.industry Afatinib Vinorelbine medicine.disease Metastatic breast cancer Trastuzumab Internal medicine medicine In patient skin and connective tissue diseases business neoplasms medicine.drug
Zdroj:	Journal of Clinical Oncology. 30:TPS649-TPS649
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2012.30.15_suppl.tps649
Popis:	TPS649 Background: Afatinib is an ErbB Family Blocker that irreversibly blocks signaling from all relevant ErbB Family dimers. Afatinib is being developed in EGFR (ErbB1)-driven (NSCLC/HNSCC) and HER2 (ErbB2)-driven (breast) malignancies. In trastuzumab-resistant, HER2-positive (SUM190) xenografts, afatinib showed antitumor activity which was superior to lapatinib and increased by addition of IV vinorelbine. Afatinib monotherapy also demonstrated clinical activity (progression-free survival [PFS] = 15.1 wk; objective response [OR] = 10%) in an open-label, single-arm, Phase II trial in patients with HER2-positive MBC after progression on trastuzumab. Methods: LUX-Breast 1 (NCT01125566) is a Phase III, open-label, multicenter trial evaluating the efficacy and safety of afatinib + vinorelbine vs. trastuzumab + vinorelbine in patients with HER2-overexpressing MBC who progressed on, or after one prior trastuzumab-based treatment regimen. Patients are randomized 2:1 to afatinib (40 mg/d oral) + vinorelbine (IV 25 mg/m2/wk) or trastuzumab (IV 2 mg/kg/wk after 4 mg/kg loading dose) + vinorelbine (IV 25 mg/m2/wk). Patients receive continuous treatment in the absence of disease progression or adverse events. Key eligibility criteria include histologically-confirmed HER2-positive BC, stage IV disease; no prior treatment with vinorelbine or HER2-targeted treatment other than trastuzumab; progression on one prior trastuzumab based regimen in either the adjuvant (or 240 sites with a recruitment target of 780 patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f034427f8824a1c061cd7ed46d6d45f6 https://doi.org/10.1200/jco.2012.30.15_suppl.tps649 Zobrazit plný text záznamu